EquityResearch3January2019COREBarclaysCapitalInc.and/oroneofitsaffiliatesdoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethatthefirmmayhaveaconflictofinterestthatcouldaffecttheobjectivityofthisreport.Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.PLEASESEEANALYSTCERTIFICATION(S)ANDIMPORTANTDISCLOSURESBEGINNINGONPAGE17.U.S.LifeScienceTools&DiagnosticsJack’sToolKit–Vol.5,Issue1:GeneSightTakeawaysfromJournalofPsychiatricPracticeArticleJack’sToolKit–WhatareyourtakeawaysonGeneSightfromarecentstudypublishedintheJournalofPsychiatricPractice?TriviaQuestion:WhatisthebestperformingLifeScienceToolsandDiagnosticsstockin2018?RecentNotes&Reports:1)2019Outlook:Tools&DxaRelativeSafeHaven,TMOOurNewTopPickBarclaysGeographicEndMarketTracker:AgilentFY1Q19PMITrackerof54.4(up0.1q/q),MettlerToledo4Q18PMITrackerof54.2(down0.9q/q),PerkinElmer4Q18PMITrackerof54.4(down1.0q/q),ThermoFisher4Q18PMITrackerof55.2(down0.6q/q),Waters4Q18PMITrackerof54.2(down1.0q/q).BarclaysFXTracker(01/02/2019):Euroweakens-0.1%w/w,UKPoundweakens-0.2%w/w,ChineseYuanstrengthens0.5%w/w,JapaneseYenstrengthens2.2%w/w,andSwissFrancstrengthens0.6%w/w.HotTopicsfortheWeek:1)Bristol-MyersSquibbannouncedtheacquisitionofCelgenefor$70billionintotalconsideration,sparkingconcernsfortheCROgroup.2)GeographicPMIstoend2018moderatedfromrecenttrends.3)LuminexcompletedtheacquisitionofMilliporeSigma’sflowcytometryportfolio.Ourcoverageuniversefinishedtheweekdown-1.3%sincelastThursday(toolsdown-4.4%,diagnosticsup0.4%,andlabs&CROsdown-0.3%).Incomparison,theS&P500wasdown-1.6%fortheweek,theRussell2000wasup1.1%,andtheNASDAQCompositewasup1.7%.StatoftheWeek:TheU.S.manufacturingPMIdeclinedsignificantly,down5.2m/mto54.1,whichremainsexpansionary.INDUSTRYUPDATEU.S.LifeScienceTools&DiagnosticsNEUTRALUnchangedU.S.LifeScienceTools&DiagnosticsJackMeehan,CFA+12125263909jack.meehan@barclays.comBCI,USMitchellPetersen+12125263367mitchell.petersen@barclays.comBCI,USA...
